Sex‐ and age‐related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long‐Term Registry

• Published in: European journal of heart failure Vol. 22; no. 1; pp. 92 - 102
• Main Authors: Polovina, Marija, Ruschitzka, Frank, Chair, GB, Jonathan Emberson, GB, Alastair Gray, GB, Aldo Maggioni, IT, Crespo‐Leiro, M., Coats, A., CY, T. Christodoulides, JP, A. Matsumori, MK, M. Otljanska, MT, D. Cassar DeMarco, Auer, J., Fruhwald, F., Dolze, T., Podczeck‐Schweighofer, A., Muslibegovic, A., Moneim, A.A., Reda, A., Aziz, R., Sobhy, H., Seronde, M‐F., Lequeux, B., Stefanadis, C., Dimitroula, T., Polgar, L., Metra, M., Bosi, S., Pirelli, S., Zanelli, E., Italiano, G., Marino, P.N., Torres, D., Arrotti, S., Inciardi, R.M., Canavosio, F.G., Fabris, E., Fresco, C., Erglis, A., Smalinskas, V., Rumbinaite, E., Kavoliuniene, A., Kardaszewicz, P., Lazorko‐Piega, M., Bartkowiak, R., Sosnowska‐Pasiarska, B., Krzeminski, A., Zabojszcz, M., Huziuk, I., Dankowski, R., Komorowska, K., Komorowska, E., Lauko‐Rachocka, A., Splawski, M., Krysiak, W., Marchel, M., Kaplon‐Cieslicka, A., Uzieblo‐Zyczkowska, B., Rozentryt, P., Kuczaj, A., Ventosa, A., Pereira, S., De Jesus, I., Magalhaes, P., Sinescu, C‐J., Macarie, C., Daha, I., Nechita, E., Simeunovic, D., Ristic, A.D., Lazic, J. Suzic, Pencic, B., Stoickov, V., Radovanovic, S., Krotin, M., Murin, J., Semjanova, H., Fras, Z., Bombek, M., Kovac, D., Anguita, M.J. Fernandez, Andres, J., Garcia‐Cosio, L., Puga‐Martinez, M., Paniagua‐Martin, M.J., Baldomero, I. Famara Hernandez, Padron, A. Lara, Rosillo, S. Ofelia, Gomez‐Bueno, M., Cano, M.J. Ruiz, Perez‐Martinez, M.T., Gracia‐Rodenas, M.R., Valero, D. Bierge, Fuente Galan, L., Diaz, J. Lopez, Blasco‐Peiro, T., Asserlund, B., Karlström, P., Olsson, B., Cavusoglu, Y.
• Format: Journal Article
• Language: English
• Published: Oxford, UK John Wiley & Sons, Ltd 01-01-2020
• Subjects: Age; Aged; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Female; Heart Failure - epidemiology; Heart Failure - therapy; Hospitalization; Humans; Male; Medicin och hälsovetenskap; Mortality; Registries; Registry; Sex; Stroke Volume; Ventricular Function, Left; Hospitalization; Registry; Mortality; Age; Sex
• ISSN: 1388-9842; 1879-0844; 1879-0844
• DOI: 10.1002/ejhf.1645

Aims
This study aimed to assess age‐ and sex‐related differences in management and 1‐year risk for all‐cause mortality and hospitalization in chronic heart failure (HF) patients.
Methods and results
Of 16 354 patients included in the European Society of Cardiology Heart Failure Long‐Term Registry, 9428 chronic HF patients were analysed [median age: 66 years; 28.5% women; mean left ventricular ejection fraction (LVEF) 37%]. Rates of use of guideline‐directed medical therapy (GDMT) were high (angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, beta‐blockers and mineralocorticoid receptor antagonists: 85.7%, 88.7% and 58.8%, respectively). Crude GDMT utilization rates were lower in women than in men (all differences: P ≤ 0.001), and GDMT use became lower with ageing in both sexes, at baseline and at 1‐year follow‐up. Sex was not an independent predictor of GDMT prescription; however, age >75 years was a significant predictor of GDMT underutilization. Rates of all‐cause mortality were lower in women than in men (7.1% vs. 8.7%; P = 0.015), as were rates of all‐cause hospitalization (21.9% vs. 27.3%; P < 0.001) and there were no differences in causes of death. All‐cause mortality and all‐cause hospitalization increased with greater age in both sexes. Sex was not an independent predictor of 1‐year all‐cause mortality (restricted to patients with LVEF ≤45%). Mortality risk was significantly lower in patients of younger age, compared to patients aged >75 years.
Conclusions
There was a decline in GDMT use with advanced age in both sexes. Sex was not an independent predictor of GDMT or adverse outcomes. However, age >75 years independently predicted lower GDMT use and higher all‐cause mortality in patients with LVEF ≤45%.